We can't find the internet
Attempting to reconnect
17994.1 PFLS-LS
Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma
Zusammenfassung
Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma
Weitere Texte
Abstract
More than 300¿000 patients are diagnosed with pancreatic ductal adenocarcinoma (PDA) each year with a median survival of only 2-17 months. 82C2 is a novel human derived monoclonal antibody with proven efficacy in mouse carcinoma models, with potential to prolong survival for PDA patients with improved efficacy compared to current standard of care. This CTI project application seeks support to advance 82C2 into clinical trials to treat PDA patients by 2019.
Beteiligte
Chad Brokopp
Wirtschaftspartner
Mabimmune Diagnostics AG Chad Brokopp Wagistrasse 13 8952 Schlieren ZH CH
Simon Hoerstrup
Kontaktperson
Simon_Philipp.Hoerstrup@usz.ch
Universität Zürich Simon Hoerstrup Rämistrasse 100 8091 Zürich ZH CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2015-07-31
- Enddatum
- 2017-10-31
- Bewilligte Gesamtkosten
- CHF 671174.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%